Literature DB >> 6417082

Importance of calcium in citric acid-induced airway constriction.

H Downes, C A Hirshman.   

Abstract

In previous studies, a 5-min inhalational challenge with 10% citric acid aerosol (0.52 M) elicited bronchoconstriction in Basenji-Greyhound (BG) dogs with hyperreactive airways but not in mongrel dogs. This response was independent of vagal reflexes because it was not attenuated by atropine. Citric acid might elicit bronchoconstriction because of acidity, calcium chelation, or some other effect of the citrate molecule. To assess these factors, barbiturate-anesthetized BG dogs were challenged (5 min) with aerosols of 10% acetic acid or a citric acid (0.48 M)/Na3citrate (0.04 M) mixture of equivalent pH, 6% Na2-ethylenediaminetetraacetic acid (EDTA), or 6% CaNa2EDTA. Each challenge was delivered in a separate week. The acidity alone was not an adequate stimulus, since pulmonary resistance (RL) was unaltered by 10% acetic acid, although markedly increased by the citric acid-Na3citrate mixture [2.2 +/- 0.4 (SE) cmH2O X l-1 X s prechallenge, 10.0 +/- 2.2 postchallenge]. Aerosols of Na2EDTA provoked a similar increase in RL (2.1 +/- 0.4 cmH2O X l-1 X s prechallenge, 9.0 +/- 1.8 postchallenge). Neither effect was attenuated by intravenous atropine (0.2 mg/kg). CaNa2EDTA caused no changes in RL. We conclude that it is the calcium chelating action of citric acid rather than its acidity that is responsible for bronchoconstriction in BG dogs with hyperreactive airways.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6417082     DOI: 10.1152/jappl.1983.55.5.1496

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  4 in total

Review 1.  HRCT imaging of airway responsiveness: effects of anesthetics.

Authors:  R H Brown
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

2.  AB569, a nontoxic chemical tandem that kills major human pathogenic bacteria.

Authors:  Cameron T McDaniel; Warunya Panmanee; Geoffrey L Winsor; Erin Gill; Claire Bertelli; Michael J Schurr; Prateek Dongare; Andrew T Paul; Seung-Hyun B Ko; Gee W Lau; Nupur Dasgupta; Amy L Bogue; William E Miller; Joel E Mortensen; David B Haslam; Phillip Dexheimer; Daniel A Muruve; Bruce J Aronow; Malcolm D E Forbes; Marek Danilczuk; Fiona S L Brinkman; Robert E W Hancock; Thomas J Meyer; Daniel J Hassett
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

3.  Adverse reactions to the non-drug constituents of nebuliser solutions.

Authors:  R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution.

Authors:  C R Beasley; P Rafferty; S T Holgate
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.